Oncology Medications


LUMAKRAS now available from Onco360!

LUMAKRAS(sotorasib) is an inhibitor of the RAS GTPase family indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy.

 Dosage and Administration 1

The recommended dose for LUMAKRAS is 960 mg (eight 120 mg tablets) orally once daily. 

Dosage Forms and Strengths 

LUMAKRAS is available in 120 mg tablets. 

  • Carton containing two bottles of 120 tablets (NDC 55513-488-02)
  • Carton containing one bottle of 240 tablets (NDC 55513-488-24) 


For more information, visit LUMAKRAS.com 

How to Refer

Limited Distribution Oncology Medications


Oncomed Dba Onco360 or
NPI# 1679618151

VONJO™ (pacritinib) for Myelofibrosis


How to Refer

 1 Prescribing Information: Amgen, Inc. accessed 6/2021. LUMAKRAS™ trademark is owned or licensed by Amgen, Inc.